{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:03:39Z","timestamp":1789419819658,"version":"build-2803163510"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Cytokines are major drivers of autoimmunity, and biologic agents targeting cytokines have revolutionized the treatment of immune-mediated diseases. Janus kinase\/signal transducer and activator of transcription (JAK-STAT) pathway represents a group of several intracellular molecules with a key role in signal pathways activated by growth factors and cytokines. These kinase proteins are associated with the signaling process of multiple key cytokines, which regulates various T-cell subpopulations and their effector cytokines. Development of novel drugs to inhibit this kinase cascade is an emerging field in clinical immunology. Thus, it is essential to have insights about the regulatory role of the JAK-STAT cytokine signaling in relation to autoimmune diseases and its applications in spondyloarthritis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>JAK-STAT kinase signaling proteins have been extensively studied in rheumatoid arthritis. Initial observations suggest that JAK-STAT kinase signaling cascade regulates activation and proliferation of the IL17<jats:sup>+<\/jats:sup> effector memory T cells and thus has a potential role in the pathogenesis of psoriasis, psoriatic arthritis and ankylosing spondylitis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Here, we provide an overview of the clinical rheumatologists about the significance of JAK-STAT signaling system in rheumatic diseases and introduce the potential application of JAK and STAT inhibitors in spondyloarthritis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000399","type":"journal-article","created":{"date-parts":[[2017,4,7]],"date-time":"2017-04-07T14:52:43Z","timestamp":1491576763000},"page":"311-316","source":"Crossref","is-referenced-by-count":21,"title":["Janus kinase\/signal transducer and activator of transcription pathways in spondyloarthritis"],"prefix":"10.1097","volume":"29","author":[{"given":"Smriti K.","family":"Raychaudhuri","sequence":"first","affiliation":[{"name":"VA Medical Center, Sacramento, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siba P.","family":"Raychaudhuri","sequence":"additional","affiliation":[{"name":"VA Medical Center, Sacramento, California"},{"name":"Division of Rheumatology, Allergy and Clinical immunology, University of California School of Medicine, Davis, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230828","doi-asserted-by":"crossref","first-page":"J314","DOI":"10.1016\/j.jaut.2009.12.001","article-title":"Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis","volume":"34","author":"Chandran","year":"2010","journal-title":"J Autoimmun"},{"key":"R2-20230828","doi-asserted-by":"crossref","first-page":"204","DOI":"10.4103\/0378-6323.132247","article-title":"Severe combined immunodeficiency mouse-psoriatic human skin xenograft model: a modern tool connecting bench to bedside","volume":"80","author":"Kundu-Raychaudhuri","year":"2014","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R3-20230828","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.4049\/jimmunol.1402175","article-title":"Distinct roles of cytoskeletal components in immunological synapse formation and directed secretion","volume":"195","author":"Ueda","year":"2015","journal-title":"J Immunol"},{"key":"R4-20230828","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-407707-2.00001-1","article-title":"The interdisciplinary science of T-cell recognition","volume":"119","author":"Huppa","year":"2013","journal-title":"Adv Immunol"},{"key":"R5-20230828","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1056\/NEJM200010053431407","article-title":"T-cell function and migration. Two sides of the same coin","volume":"343","author":"von Andrian","year":"2000","journal-title":"N Engl J Med"},{"key":"R6-20230828","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1038\/jid.2008.38","article-title":"FR255734, a humanized, Fc-silent, anti-CD28 antibody improves psoriasis in the SCID mouse-psoriasis xenograft model","volume":"128","author":"Raychaudhuri","year":"2008","journal-title":"J Invest Dermatol"},{"key":"R7-20230828","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1084\/jem.173.3.721","article-title":"Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation","volume":"173","author":"Linsley","year":"1991","journal-title":"J Exp Med"},{"key":"R8-20230828","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11010-011-1036-6","article-title":"IL-17 receptor and its functional significance in psoriatic arthritis","volume":"359","author":"Raychaudhuri","year":"2012","journal-title":"Mol Cell Biochem"},{"key":"R9-20230828","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s10067-016-3263-4","article-title":"IL-23\/IL-17 axis in spondyloarthritis-bench to bedside","volume":"35","author":"Raychaudhuri","year":"2016","journal-title":"Clin Rheumatol"},{"key":"R10-20230828","doi-asserted-by":"crossref","first-page":"e1005082","DOI":"10.1371\/journal.pcbi.1005082","article-title":"Leukocyte motility models assessed through simulation and multiobjective optimization-based model selection","volume":"12","author":"Read","year":"2016","journal-title":"PLoS Comput Biol"},{"key":"R11-20230828","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJMra1202117","article-title":"JAKs and STATs in immunity, immunodeficiency, and cancer","volume":"368","author":"O'Shea","year":"2013","journal-title":"N Engl J Med"},{"key":"R12-20230828","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"R13-20230828","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1242\/jcs.00963","article-title":"The JAK\/STAT signalling pathway","volume":"117","author":"Rawlings","year":"2004","journal-title":"J Cell Sci"},{"key":"R14-20230828","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-1119(02)00398-0","article-title":"Signalling through the JAK\/STAT pathway, recent advances and future challenges","volume":"285","author":"Kisseleva","year":"2002","journal-title":"Gene"},{"key":"R15-20230828","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J Med Chem"},{"key":"R16-20230828","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1126\/science.1087061","article-title":"Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor","volume":"302","author":"Changelian","year":"2003","journal-title":"Science"},{"key":"R17-20230828","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.0105-2896.2005.00220.x","article-title":"J AK3, severe combined immunodeficiency, and a new class of immunosuppressive drugs","volume":"203","author":"Esu","year":"2005","journal-title":"Immunol Rev"},{"key":"R18-20230828","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1476-9255-7-41","article-title":"Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis","volume":"7","author":"Meyer","year":"2010","journal-title":"J Inflamm (Lond)"},{"key":"R19-20230828","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jdermsci.2011.11.011","article-title":"Podoplanin expression in wound and hyperproliferative psoriatic epidermis: regulation by TGF\u03b2 and STAT3 activating cytokines, IFN\u03b3, IL6, and IL22","volume":"65","author":"Honma","year":"2012","journal-title":"J Dermatol Sci"},{"key":"R20-20230828","first-page":"440","article-title":"The JAK inhibitor tofacitinib suppresses synovial JAK1STAT signalling in rheumatoid arthritis","volume":"71","author":"Boyle","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R21-20230828","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/annrheumdis-2014-207201","article-title":"Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors","volume":"75","author":"Gao","year":"2016","journal-title":"Ann Rheum Dis Ann Rheum Dis"},{"key":"R22-20230828","doi-asserted-by":"crossref","first-page":"e0164080","DOI":"10.1371\/journal.pone.0164080","article-title":"JAK3 as an emerging target for topical treatment of inflammatory skin diseases","volume":"11","author":"Alves de Medeiros","year":"2016","journal-title":"PLoS One"},{"key":"R23-20230828","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2016-211046","article-title":"Regulatory role of the JAK STAT kinase signaling system on the IL-23\/IL-17 cytokine axis in psoriatic arthritis","author":"Raychaudhuri","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R24-20230828","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.clim.2010.05.003","article-title":"Analysis of JAK2 and STAT3 polymorphisms in patients with ankylosing spondylitis in Chinese Han population","volume":"136","author":"Chen","year":"2010","journal-title":"Clin Immunol"},{"key":"R25-20230828","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.mrfmmm.2010.01.017","article-title":"Genetic factors in chronic inflammation: single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn's disease in a New Zealand population","volume":"690","author":"Ferguson","year":"2010","journal-title":"Mutat Res"},{"key":"R26-20230828","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nrd1441","article-title":"A new modality for immunosuppression: targeting the JAK\/STAT pathway","volume":"3","author":"O'Shea","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"R27-20230828","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"key":"R28-20230828","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1365-2133.2012.11168.x","article-title":"Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study","volume":"167","author":"Papp","year":"2012","journal-title":"Br J Dermatol"},{"key":"R29-20230828","first-page":"252","article-title":"Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regions","volume":"13","author":"Menter","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"R30-20230828","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/bjd.14403","article-title":"A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1\/JAK2 inhibitor, in patients with moderate-to-severe psoriasis","volume":"174","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"key":"R31-20230828","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"(Suppl 10)","key":"R32-20230828","article-title":"Treatment with tofacitinib is associated with clinically meaningful reductions in axial MRI inflammation in patients with ankylosing spondylitis [abstract]","volume":"68","author":"Maksymowych","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"(Suppl 10)","key":"R33-20230828","article-title":"Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, or adalimumab in patients with active psoriatic arthritis and an inadequate response to conventional synthetic DMARDs: a randomized, placebo-controlled, phase 3 trial [abstract]","volume":"68","author":"Mease","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R34-20230828","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1136\/annrheumdis-2014-207178","article-title":"Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs","volume":"75","author":"Charles-Schoeman","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R35-20230828","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","article-title":"Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial","volume":"159","author":"Kremer","year":"2013","journal-title":"Ann Intern Med"},{"key":"R36-20230828","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/art.38745","article-title":"Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis","volume":"66","author":"Winthrop","year":"2014","journal-title":"Arthritis Rheumatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201707000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T05:37:53Z","timestamp":1693201073000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201707000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000399","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7]]}}}